AGENDA ITEM

Wednesday, February 26th

8:00 Welcome & Introductions

8:30 Ebola Vaccine

Introduction
Review of Ebola virus disease and rVSVΔG-ZEBOV-GP vaccine
GRADE
ETR and summary of WG considerations and proposed policy options

10:00 Break
10:30 Ebola Vaccine, continued

12:00 Lunch
1:15 Public Comment
2:15 Break

2:30 VOTE

Ebola Vaccine

2:45 2019 Novel Coronavirus (2019-nCov) Informational Session

3:30 3:45 Influenza Vaccines

Introduction
Older Adult (65+) Adjuvanted Quadrivalent Influenza Vaccine (aIV4)
2019-20 U.S. Influenza Surveillance Update
2019-20 U.S. Influenza Vaccine Effectiveness Update
Safety of Adjuvanted vs. High-Dose Inactivated Influenza Vaccines in Older Adults
Summary and Work Group Considerations

5:00 Adjourn

Thursday, February 27th

8:30 Unfinished Business and Agency Updates

9:00 Rabies Vaccine

Introduction
Background to PrEP, Vaccine Safety, and Work Group Considerations
Rabies Vaccine Schedule & Duration of Immunity (Systematic Review Data)

Work Group Next Steps

10:00 Break
10:30 Dengue Vaccine

Introduction
Dengue Vaccine Acceptability in Puerto Rico
SAGE Perspective on Dengvaxia
Summary of Work Group Considerations

12:00 Lunch
1:00 Polio Informational Session
Polio and Polio Policy in the United States – The Oral Polio Vaccine to Inactivated Polio Vaccine Switch
Global Polio Eradication: Progress and Prospects

Dr. Walt Orenstein (Emory University)
Mr. John Salamone (Former ACIP Member)
Dr. Stephen Cochi (CDC/CGH)

2:00 Hepatitis B Vaccine
Work Group Update

Dr. Sharon Frey (ACIP, WG Chair)

2:10 General Best Practices
Introduction
Update on Recent Postings

Dr. Paul Hunter (ACIP, WG Chair)
Dr. Andrew Kroger (CDC/NCIRD)

2:20 Vaccine Supply Update

Dr. Jeanne Santoli (CDC/NCIRD)

2:30 Acronyms

CDC Centers for Disease Control & Prevention
CMS Centers for Medicare and Medicaid Services
DoD Department of Defense
DVA Department of Veterans Affairs
ETr Evidence to Recommendations Framework
FDA Food and Drug Administration
GRADE Grading of Recommendations Assessment, Development and Evaluation
HRSA Health Resources and Services Administration
IHS Indian Health Service
NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]
OIDP Office of Infectious Disease and HIV/AIDS Policy
PrEP Pre-exposure Prophylaxis
SAGE Strategic Advisory Group of Experts
WG Work Group
WHO World Health Organization
VE Vaccine Effectiveness

Adjourn